BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Asthma
Interventions
COMBINATION_PRODUCT

Benralizumab

Participants will receive benralizumab subcutaneously.

Trial Locations (25)

3168

Research Site, Clayton

4000

Research Site, Liège

5065

Research Site, Toorak Gardens

5101

Research Site, Namur

8003

Research Site, Barcelona

12540

Research Site, Villarreal (Castellón)

15801

Research Site, DuBois

22908

Research Site, Charlottesville

28007

Research Site, Madrid

33324

Research Site, Plantation

33470

Research Site, Loxahatchee Groves

34295

Research Site, Montpellier

39008

Research Site, Santander

40536

Research Site, Lexington

46143

Research Site, Greenwood

63110

Research Site, St Louis

75708

Research Site, Tyler

77598

Research Site, Webster

94598

Research Site, Walnut Creek

1649-035

Research Site, Lisbon

4100-180

Research Site, Porto

08006

Research Site, Barcelona

08017

Research Site, Barcelona

BND9 6RJ

Research Site, Bradford

NG5 1PB

Research Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY